Prime Medicine, Inc. Common Stock
PRMEStock
$3.22−18.65%52W
Market Cap$630.35M
P/E—
Div yield—
Beta2.25
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-23.07%
Price vs S&P 500 (4W)21.01%
VGM Score29.34
Market Capitalization$630.35M
Earnings Surprise History
Q1 26-0.28est. -0.26
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.05
4.05
4.05
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PRMEPrime Medicine, Inc. Common Stock | F | D | D | $3.22 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Prime Medicine Inc develops genetic therapies based on Prime Editing, a next-generation gene-editing technology designed to precisely correct genetic mutations and restore normal cellular function. The company targets rare and severe diseases with significant unmet medical needs across multiple therapeutic areas. Prime Editing's broader applicability compared to earlier gene-editing approaches positions the company to address a substantial market opportunity.